183
Participants
Start Date
January 20, 2021
Primary Completion Date
October 28, 2022
Study Completion Date
November 1, 2022
JS005 (recombinant humanized monoclonal antibody against IL-17A)
Subcutaneous injection
JS005 placebo
Subcutaneous injection
Chinese PLA General Hospital, Beijing
Peking University People's Hospital, Beijing
Peking University Third Hospital, Beijing
Beijing Tsinghua Changgung Hospita, Beijing
First Hospital of Jilin University, Changchun
Second Affiliated Hospital of Harbin Medical University, Haerbin
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai
Shanghai Skin Disease Hospital, Shanghai
Dermatology Hospital, Chinese Academy of Medical Sciences, Nanjing
Affiliated Hospital of Jiangsu University, Zhenjiang
Dermatology Hospital affiliated to Shandong First Medical University, Jinan
Qilu Hospital of Shandong University, Jinan
The First Affiliated Hospital of Shanxi Medical University, Taiyuan
Tianjin Medical University General Hospital, Tianjin
Affiliated Hospital of Tianjin Academy of Traditional Chinese Medicine, Tianjin
The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou
Zhejiang Provincial People's Hospital, Hangzhou
The Second Affiliated Hospital of Nanchang University, Nanchang
The First Affiliated Hospital of Chongqing Medical University, Chongqing
Guangdong Provincial People's Hospital, Guangzhou
Dermatology Hospital of Southern Medical University, Guangzhou
The First Hospital of Hebei Medical University, Shijiazhuang
Shanghai Junshi Bioscience Co., Ltd.
OTHER